Reffo Verónica L, Chiarella Paula, Bruzzo Juan, Bustuoabad Oscar D, Ruggiero Raúl A
División Medicina Experimental, ILEX-CONICET, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires.
Medicina (B Aires). 2008;68(4):301-4.
Up to date, most attempts to use immunotherapy to cause the regression of animal and human established tumors have not been successful. Former experiments have postulated that this failure could be attributed, at least in part, to a lack of immunogenicity of spontaneous tumors. In this paper, we have investigated whether this lack of immunogenicity can be attributed to the absence of tumor antigens or to the existence of tolerogenic mechanisms preventing such antigens from initiating an antitumor immune response. We have used two murine tumors a non-immunogenic spontaneous lymphoma (LB) and a strongly immunogenic methylcholanthrene-induced fibrosarcoma (MC-C) together with a vaccination strategy based on the inoculation of dendritic cells (DC) loaded with a tumor lysate. When DC were pulsed with LB lysate (DC+LB), no maturation of DC was achieved in vitro and no protection against LB implants after DC+LB inoculation was observed in vivo. On the other hand, when DC were pulsed with MC-C lysate (DC+MC-C), maturation of DC was observed along with a strong protection against MC-C implants after DC+MC-C inoculaton. Finally, when DC were pulsed with both LB and MC-C lysates (DC+LB+MC-C), maturation of DC and protection against LB implants were achieved. Since no immune cross reaction between MC-C and LB was ever observed, the most likely interpretation is that LB bears specific tumor antigens but lacks other signals to achieve DC maturation. These signals would be provided by MC-C which would enable DC to mature and to initiate an effective anti-LB immune response.
到目前为止,大多数使用免疫疗法使动物和人类已形成肿瘤消退的尝试都未成功。先前的实验推测,这种失败至少部分可归因于自发肿瘤缺乏免疫原性。在本文中,我们研究了这种免疫原性的缺乏是由于肿瘤抗原的缺失,还是由于存在耐受机制阻止此类抗原引发抗肿瘤免疫反应。我们使用了两种小鼠肿瘤,一种是无免疫原性的自发淋巴瘤(LB)和一种强免疫原性的甲基胆蒽诱导的纤维肉瘤(MC-C),以及一种基于接种负载肿瘤裂解物的树突状细胞(DC)的疫苗接种策略。当用LB裂解物脉冲DC(DC+LB)时,体外未实现DC的成熟,并且在体内接种DC+LB后未观察到对LB植入物的保护作用。另一方面,当用MC-C裂解物脉冲DC(DC+MC-C)时,观察到DC的成熟以及在接种DC+MC-C后对MC-C植入物的强大保护作用。最后,当用LB和MC-C裂解物两者脉冲DC(DC+LB+MC-C)时,实现了DC的成熟以及对LB植入物的保护。由于从未观察到MC-C和LB之间的免疫交叉反应,最可能的解释是LB携带特定的肿瘤抗原,但缺乏其他实现DC成熟的信号。这些信号将由MC-C提供,这将使DC能够成熟并启动有效的抗LB免疫反应。